These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26774049)

  • 1. A methodology concern of the meta-analysis of antiviral therapy for chronic hepatitis B virus infection in adults.
    Zhang ZF; Duan ZJ
    Hepatology; 2016 Sep; 64(3):1001-3. PubMed ID: 26774049
    [No Abstract]   [Full Text] [Related]  

  • 2. [Predictors of lamivudine resistance in patients with chronic hepatitis B virus infection].
    Heo J; Cho M; Cho BM; Lee SM; Kim TO; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2007 Jun; 13(2):157-65. PubMed ID: 17585189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatitis B virus e antigen plays an important role in the treatment for chronic hepatitis B].
    Kanda T; Nakamoto S; Sasaki R; Wu S
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():531-4. PubMed ID: 26845991
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of interferon-alpha treatment in children with hepatitis B e antigen-positive chronic hepatitis B virus infection: a meta-analysis of follow-up for six months to two years].
    Lin ZQ; Fang F; Guo ZF; Chen Q
    Zhonghua Er Ke Za Zhi; 2007 Aug; 45(8):592-8. PubMed ID: 18021533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis.
    Njei B; Gupta N; Ewelukwa O; Ditah I; Foma M; Lim JK
    Liver Int; 2016 May; 36(5):634-41. PubMed ID: 26352650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to: "Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land".
    Zhao P
    J Hepatol; 2018 Nov; 69(5):1205-1206. PubMed ID: 30173954
    [No Abstract]   [Full Text] [Related]  

  • 9. Response-guided therapy by hepatitis B surface antigen level for peginterferon therapy: what is next?
    Chan HL
    J Gastroenterol Hepatol; 2012 Mar; 27(3):420-1. PubMed ID: 22353347
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antiviral treatment of HBeAg positive chronic hepatitis B].
    Wang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):540. PubMed ID: 16042897
    [No Abstract]   [Full Text] [Related]  

  • 11. Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.
    Hultgren C; Weiland O; Milich DR; Sällberg M
    Clin Infect Dis; 1999 Dec; 29(6):1575-7. PubMed ID: 10585820
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

  • 13. Peginterferon therapy for chronic hepatitis B: one size fits all?
    Chan HL
    Gut; 2013 Feb; 62(2):185-7. PubMed ID: 22942237
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of antiviral therapy on the cellular immune response in patients with chronic hepatitis B.
    Luo G; Feng X; Huang Y; Yi T; Wang D; Guo X; Yan H; Zhang G
    Mol Med Rep; 2015 Feb; 11(2):1284-91. PubMed ID: 25371014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of HBeAg negative chronic hepatitis B].
    Jia JD
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):539. PubMed ID: 16042896
    [No Abstract]   [Full Text] [Related]  

  • 16. [HBeAg-negative chronic hepatitis].
    Ibragimova MM; Krel' PE; Abdurakhmanov DT
    Ter Arkh; 2004; 76(2):87-91. PubMed ID: 15106425
    [No Abstract]   [Full Text] [Related]  

  • 17. Posttreatment Hepatitis B Surface Antigen Seroreversion: The Bane of Combination Therapy in Chronic Hepatitis B?
    Sonneveld MJ; Brouwer WP; van der Meer AJ
    Gastroenterology; 2016 May; 150(5):1254-1255. PubMed ID: 27020333
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral antivirals for chronic hepatitis B.
    Min AD; Dienstag JL
    Clin Liver Dis; 2007 Nov; 11(4):851-68, ix. PubMed ID: 17981232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus serology to predict antiviral response in chronic hepatitis B.
    Kim BK; Han KH; Ahn SH
    Digestion; 2011; 84 Suppl 1():29-34. PubMed ID: 22156483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis].
    Wang FS; Zhang JY
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):164-6. PubMed ID: 19554778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.